Antibody and Biologic Design

Antibody and biologic design sits where structure, sequence, immunology, and manufacturing meet. A designed binder is useful only if affinity, specificity, expression, stability, safety, and developability survive the same program.

Learning Objectives

• Separate binder design from therapeutic biologic development.
• Identify developability constraints that structure models do not settle.
• Use assay cascades for affinity, specificity, and manufacturability.

TL;DR

AI design methods help generate and prioritize binders. Therapeutic biologics still require assay cascades, liability screening, cell-based testing, and manufacturing review.

Introduction

Protein design systems now support binder and scaffold design, but antibodies add constraints from immune repertoires, CDR loop geometry, epitope context, glycosylation, Fc behavior, and developability. RFdiffusion and AlphaFold 3 are relevant to this space because they address structure and interaction modeling (Watson et al., 2023; Abramson et al., 2024).

Demonstrated

Demonstrated capability includes structure-guided binder design, antibody structure modeling, and sequence optimization workflows for selected targets. RFdiffusion demonstrated protein binder design tasks with experimental follow-up (Watson et al., 2023). AlphaFold 3 demonstrated biomolecular interaction prediction that includes protein complexes relevant to binder assessment (Abramson et al., 2024).

Evidence Anchor	What It Supports	Practical Constraint
RFdiffusion	Designed binders and constrained protein generation	Therapeutic behavior requires downstream assays
AlphaFold 3	Complex prediction for biomolecular interactions	Binding affinity and function are not guaranteed by a pose
ProteinMPNN	Sequence design around backbones	Developability filters remain external

Theoretical

Theoretical capability includes antibody libraries designed around target epitopes with predictable affinity maturation and low developability risk. That goal is plausible for constrained domains, but target biology and manufacturability still determine program success.

Beyond Current Capabilities

Beyond current capabilities includes end-to-end biologic development from antigen sequence to clinical candidate without immunological, pharmacological, and manufacturing testing. No model removes the need for those gates.

Practice Notes

• Keep epitope, paratope, isotype, format, and intended mechanism separate.
• Screen for aggregation, viscosity, expression, liabilities, immunogenicity, and polyspecificity.
• Use orthogonal assays when structural models disagree with binding data.
• Treat high-affinity designs without specificity data as incomplete.